NCT03849768 2023-01-20A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in PatientsJiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3 Unknown429 enrolled 18 charts